Andrade JG, Verma A, Mitchell LB, et al; CCS Atrial Fibrillation Guidelines Committee. 2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Can J Cardiol. 2018 Nov;34(11):1371-1392. doi: 10.1016/j.cjca.2018.08.026. PubMed PMID: 30404743.
January CT, Wann LS, Alpert JS, et al; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014 Dec 2;130(23):e199-267. doi: 10.1161/CIR.0000000000000041. Epub 2014 Mar 28. Erratum in: Circulation. 2014 Dec 2;130(23):e272-4. PubMed PMID: 24682347; PubMed Central PMCID: PMC4676081.
Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013 Dec;10(12):1932-63. doi: 10.1016/j.hrthm.2013.05.014. Epub 2013 Aug 30. Review. PubMed PMID: 24011539.
Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013 Aug;34(29):2281-329. doi: 10.1093/eurheartj/eht150. Epub 2013 Jun 24. PubMed PMID: 23801822.
American College of Cardiology Foundation; American Heart Association; European Society of Cardiology; Heart Rhythm Society, Wann LS, Curtis AB, Ellenbogen KA, et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2013 May 7;127(18):1916-26. doi: 10.1161/CIR.0b013e318290826d. Epub 2013 Apr 1. PubMed PMID: 23545139.
Camm AJ, Lip GY, De Caterina R, et al; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012 Nov;33(21):2719-47. doi: 10.1093/eurheartj/ehs253. Epub 2012 Aug 24. Erratum in: Eur Heart J. 2013 Mar;34(10):790. Eur Heart J. 2013 Sep;34(36):2850-1. PubMed PMID: 22922413.
Tracy CM, Epstein AE, Darbar D, et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Heart Rhythm Society. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. [corrected]. Circulation. 2012 Oct 2;126(14):1784-800. doi: 10.1161/CIR.0b013e3182618569. Epub 2012 Sep 10. Erratum in: Circulation. 2013 Jan 22;127(3):e357-9. Heart Rhythm Society [added]. PubMed PMID: 22965336.
Pediatric and Congenital Electrophysiology Society (PACES); Heart Rhythm Society (HRS); American College of Cardiology Foundation (ACCF); American Heart Association (AHA); American Academy of Pediatrics (AAP); Canadian Heart Rhythm Society (CHRS), Cohen MI, Triedman JK, Cannon BC, et al. PACES/HRS expert consensus statement on the management of the asymptomatic young patient with a Wolff-Parkinson-White (WPW, ventricular preexcitation) electrocardiographic pattern: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS). Heart Rhythm. 2012 Jun;9(6):1006-24. doi: 10.1016/j.hrthm.2012.03.050. Epub 2012 May 10. PubMed PMID: 22579340.
European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010 Oct;31(19):2369-429. doi: 10.1093/eurheartj/ehq278. Epub 2010 Aug 29. Erratum in: Eur Heart J. 2011 May;32(9):1172. PubMed PMID: 20802247.
Definition, Etiology, PathogenesisTop
Patients after myocardial infarction (MI) can develop a myriad of ventricular arrhythmias. Polymorphic ventricular tachycardia (VT) or ventricular fibrillation (VF) can develop in the acute phase of MI or during periods of acute ischemia at a later stage. Scar-related arrhythmia (chronic phase of ischemic cardiomyopathy) is usually manifested as monomorphic VT, either nonsustained (NSVT) or sustained. Sustained monomorphic VT usually develops in patients with more extensive necrosis and depressed left ventricular (LV) function; this type of VT is related to a reentrant circuit within the myocardial scar.
Clinical Features and Natural HistoryTop
NSVT may be asymptomatic. However, sustained VT occurring in this group of patients, particularly during faster rhythms (>150-170 beats/min), may cause significant hemodynamic abnormalities leading to hypotension, chest pain, heart failure, syncope, or cardiac arrest (VT can transform into VF).
Electrocardiography (ECG): see Figure 3.3-1. Polymorphic VT or VF is manifested as a chaotic ventricular rhythm. Sustained monomorphic VT presents as a wide-complex tachycardia and needs to be differentiated from supraventricular tachycardia with aberrancy and from antidromic atrioventricular reentrant tachycardia. The morphology of the VT can help define the origin (myocardial earliest activation point). For example, in a patient with a previous apical MI (the left anterior descending artery [LAD] territory), a monomorphic VT would have predominantly negative QRS in the precordial leads.
Classification of antiarrhythmic drugs: see Table 3.4-1.
Antiarrhythmic agents: see Table 3.4-2.
1. Optimize ischemic heart disease treatment, including revascularization and treatment of LV dysfunction or heart failure. All patients should receive a beta–blocker unless contraindicated.
2. Antiarrhythmic medications: Patients who had VT or VF while on beta-blocker therapy may be considered for a trial of amiodarone to prevent arrhythmia recurrence. Although sotalol is less effective, it is still an option for patients who cannot use amiodarone.
3. Catheter ablation of VT was shown to reduce recurrent episodes of VT, particularly in patients already receiving amiodarone.
4. Implantable cardioverter-defibrillator (ICD): This is indicated for secondary prevention of sudden cardiac death (SCD) in patients who have survived VF or VT causing hemodynamic instability unless the episode occurred in the setting of acute ischemia with a treatable cause. The primary indication (individuals at risk for SCD who have not had an episode yet) includes patients >40 days after MI with an LV ejection fraction ≤30 to 35%. If ICD implantation is not possible despite indications (lack of patient consent, contraindications, lack of resources), administer amiodarone or sotalol.
Figure 3.4-12. Acute management of patients with regular tachycardia. Adapted from guidelines by the American College of Cardiology, American Heart Association, and European Society of Cardiology.